

# DRUG DETERMINATION POLICY

**Title:** DDP-04 Miscellaneous Gastrointestinal (GI) Agents

**Effective Date:** 2/28/24



Physicians Health Plan  
PHP Insurance Company  
PHP Service Company

## Important Information - Please Read Before Using This Policy

The following policy applies to health benefit plans administered by PHP and may not be covered by all PHP plans. Please refer to the member's benefit document for specific coverage information. If there is a difference between this general information and the member's benefit document, the member's benefit document will be used to determine coverage. For example, a member's benefit document may contain a specific exclusion related to a topic addressed in a coverage policy.

Benefit determinations for individual requests require consideration of:

1. The terms of the applicable benefit document in effect on the date of service.
2. Any applicable laws and regulations.
3. Any relevant collateral source materials including coverage policies.
4. The specific facts of the particular situation.

Contact PHP Customer Service to discuss plan benefits more specifically.

### 1.0 Policy:

This policy describes the determination process for coverage of specific drugs.

This policy does not guarantee or approve Benefits. Coverage depends on the specific Benefit plan. Pharmacy Benefit Determination Policies are not treatment recommendations and should not be used as treatment guidelines.

### 2.0 Background or Purpose:

Xifaxan, Viberzi, and Lotronex, are indicated for several diagnoses. These criteria were developed and implemented to ensure appropriate use for the intended diagnoses and disease severity.

### 3.0 Clinical Determination Guidelines:

Document the following with chart notes:

- I. Irritable Bowel Syndrome with diarrhea (IBS-D): Xifaxan, Lotronex, and Viberzi [must meet all listed below]:
  - A. Diagnosis and severity: fulfill Rome IV IBS criteria [see Appendix I].
  - B. Other therapies: Trials of two over-the-counter agents and three prescription agents from different classes listed below are required unless all are contraindicated. Trials must result in an inadequate response after four consecutive months of use per medication or severe adverse effects.
    1. Over-the-counter agents [must meet one of each drug class listed below]:
      - a. Fiber or psyllium
      - b. Probiotics.
    2. Prescription agents [must meet one of each drug class listed below]:
      - a. Antispasmodics: dicyclomine, hyoscyamine.
      - b. Anti-diarrheal medications: loperamide.
      - c. Antidepressants: tricyclic, selective serotonin reuptake inhibitors (SSRIs).

### C. Dosage regimen

1. Xifaxan (rifaximin) treatment course: 550mg three times per day for two weeks (#42 tabs for two weeks).
2. Lotronex (alesetron): 0.5mg twice daily for four weeks if tolerated, but inadequate response, may increase to 1mg twice daily. If the response is inadequate after four weeks of 1mg twice daily, then discontinue treatment.
3. Viberzi (eluxadoline): maximum of 100mg two times daily

### D. Approval

1. Initial:
  - a. Xifaxan: one course (two weeks)
  - b. Lotronex: three months
  - c. Viberzi: six months
2. Re-approval: reoccurrence or continued symptoms
  - a. Xifaxan: one course (maximum number of times approved is a total of three courses)
  - b. Viberzi: one year

### E. Exclusions.

1. Lotronex: use in male patients

## II. Traveler's Diarrhea: Xifaxan

### A. Diagnosis and severity [must meet all listed below]:

1. Symptoms: mild cramps/urgent loose stools to severe abdominal pain, fever, vomiting, and bloody diarrhea.
2. Onset: six hours to two days incubation for bacterial and viral pathogens.
3. Travel in high-risk areas: Asia, the Middle East, Africa, Mexico, and Central/South America.
4. Confirmed diagnosis of *E. coli* (non-invasive).

### B. Other therapies: Trials of one anti-motility agent and one antibiotic are required unless all are contraindicated. Trials must result in an inadequate response after four consecutive months (except antibiotics) of use per medication or severe adverse effects.

1. Anti-motility agents: loperamide, diphenoxylate.
2. Antibiotics: azithromycin 1,000mg once or 500mg daily for one to three days.

### C. Dosage regimen.

1. Xifaxan (rifaximin oral) treatment course: 200mg three times daily for three days.

### D. Approval: one course per initial and repeat episodes.

### III. Hepatic Encephalopathy: Xifaxan.

#### A. Diagnosis and severity [refer to Appendix II]:

1. Severity: Overt hepatic encephalopathy grade II to IV.

#### B. Treatment indications for Overt hepatic encephalopathy [must meet one listed below]:

1. Active treatment: spontaneous or precipitated episode of hepatic encephalopathy
2. Secondary prophylaxis: post overt hepatic encephalopathy episode
3. Primary prophylaxis: prevent those at high risk for an episode of overt hepatic encephalopathy with cirrhosis.

#### C. Other therapies: A trial of lactulose is required unless contraindicated. Trial must result in an inadequate response after four consecutive months of use or severe adverse effects.

1. Lactulose: dose titrated up to three stools per day

#### D. Dosage regimen for approval:

1. Must be in combination therapy with lactulose unless contraindicated (no Xifaxan monotherapy)
2. Dose: Xifaxan 550 mg two times daily

#### E. Approval duration

1. Initial: six months
2. Re-approval: six months
3. Discontinue: precipitating factors controlled, improved liver function or nutritional status

### IV. Non-FDA-approved indications.

#### A. Compendium supported (Lexicomp™): compendium support for the use of a drug for a non-FDA approved indication.

#### B. Small Intestinal Bacterial Overgrowth [must meet all criteria listed below]:

1. Age: at least 12 years old
2. Diagnosis and severity [must meet one symptom and aspirate concentration listed below]:
  - a. Symptoms: bloating, flatulence, abdominal discomfort, or chronic watery diarrhea.
  - b. Jejunal aspirate culture: bacterial concentration of over  $10^3$  colony forming units/ml.
3. Other therapies: Trials of two antibiotics are required unless all are contraindicated. Trials must result in an inadequate response after two consecutive weeks of use per medication or severe adverse effects
  - a. Antibiotics: ciprofloxacin, metronidazole, amoxicillin-clavulanate, trimethoprim-sulfamethoxazole.

4. Dosage regimen

- a. Xifaxan (rifaximin) treatment course: 550mg three times per day for two weeks (#42 tabs per two weeks).

5. Approval

- a. Initial: one course
- b. Re-approval: one course (maximum number of times approved is a total of three courses)

#### 4.0 Coding:

COVERED PRODUCTS – PHARMACY BENEFIT		
Brand Name	Generic Name	Prior Approval
Dificid	fidaxomicin	Y
Lotronex	alesetron	Y
Viberzi	eluxadoline	Y
Xifaxan	rifaximin	Y

#### 5.0 References, Citations & Resources:

1. Lexicomp Online®, Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; Xifaxan, Lotronex Viberzi, Zinplava, Dificid accessed December 2022.
2. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. Am J Gastroenterol 2014;109:S2-S26.
3. American Gastroenterological Association Guideline on the Pharmacological Management of Irritable Bowel Syndrome. Gastroenterol 2014;147:1146-1148.
4. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guidelines by AASLD and EASL.
5. Centers for Disease Control & Prevention (2014).Yellowbook. Chapter 2 - the pre-travel-consultation. Traveler's Diarrhea. Retrieved from <http://.cdc.gov/travel/yellowbook/2014>.
6. Xifaxan [Package Insert], Whitby, Ontario, Salix; 2015.
7. Guidelines for Diagnosis, Treatment and Prevention of *Clostridium difficile* Infections. Am J of Gastroenterol 2014; 108: 478-498.
8. Bezlotoxumab for Prevention of recurrent *C. difficile* infection. N Engl J Med 2017;376(4); 305-317.
9. UpToDate, Post TW (Ed), Waltham, MA
  - Treatment of Irritable Bowel Syndrome in Adults With Idiopathic Pulmonary Fibrosis. accessed 12/23.
  - Treatment of Irritable Bowel syndrome in adults. accessed December 2023.
  - Travelers' diarrhea: Clinical manifestations, diagnosis, and treatment LaRocque, R et al. accessed December 2023.
  - Clostridioides (formerly Clostridium) difficile infection in adults: Treatment and prevention Kelly, KP et al accessed December 2023.
  - Small Intestinal Bacterial Overgrowth: Management. Pimentel et al accessed Dec 2023.
10. ACG Clinical Guidelines: Prevention, Diagnosis and Treatment of *C. difficile* Infections Am J of Gastroenterol. 2021;116:1124-1147.
11. Clinical Practice Guidelines by the Infectious Disease Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on the Management of *C difficile* Infections in Adults. CID 2021;73 (1 September).
12. ACG Clinical Guidelines: Small Intestinal Bacterial Overgrowth. The American Journal of Gastroenterology: February 2020 - Volume 115 - Issue 2 - p 165-178  
doi:10.14309/ajg.0000000000000501

#### 6.0 Appendices:

See pages 6-8.

#### 7.0 Revision History:

Original Effective Date: August 26, 2015

Next Review Date: 01/27/2022

Revision Date	Reason for Revision
---------------	---------------------

<b>Revision Date</b>	<b>Reason for Revision</b>
2/19	Transitioned to new format
12/19	Annual review; replaced abbreviations, reformatting done, revised IBS-D other therapies, updated references as needed.
4/20	Off-cycle review; formatting, changed other therapies language, antibiotic treatment for traveler's diarrhea, C. dif lab test, Appendix II, add Difucid to patient safety table.
12/20	Annual review, replaced abbreviations, reformatted, updated references, added Lotronex, approved by P&T 2/24/21
5/21	Off-cycle review; clarified instructions, replaced abbreviations, added diagnosis of small intestinal bacterial overgrowth
11/21	Off-cycle review, clarified Xifaxan treatment course as two weeks, revised initial severe c. Diff tx to Difucid
2/22	Annual review; Additional changes from Feb P & T; added references
12/22	Annual review; added guidelines; clarified other therapies; removed Zinplava table from coding as it is no longer on the formulary
12/23	Annual review; updated other therapies language and coding section, deleted C. Diff section because PA removed from Difucid, remove Safety and Patient monitoring table

## Rome IV Diagnostic Criteria for IBS

- Recurrent abdominal pain, on average, at least 1 day per week in the previous 3 months, associated with 2 or more of the following criteria:
  - Defecation
  - A change in stool frequency
  - A change in stool form (appearance)
- Criteria must be fulfilled for the last 3 months, with symptom onset at least 6 months before diagnosis



**TABLE 2. WHC AND CLINICAL DESCRIPTION**

WHC INCLUDING MHE	ISHEN	DESCRIPTION	SUGGESTED OPERATIVE CRITERIA	COMMENT
Unimpaired		No encephalopathy at all, no history of HE	Tested and proved to be normal	
Minimal	Covert	Psychometric or neuropsychological alterations of tests exploring psychomotor speed/executive functions or neurophysiological alterations without clinical evidence of mental change	Abnormal results of established psychometric or neuropsychological tests without clinical manifestations	No universal criteria for diagnosis  Local standards and expertise required
Grade I		<ul style="list-style-type: none"> <li>• Trivial lack of awareness</li> <li>• Euphoria or anxiety</li> <li>• Shortened attention span</li> <li>• Impairment of addition or subtraction</li> <li>• Altered sleep rhythm</li> </ul>	Despite oriented in time and space (see below), the patient appears to have some cognitive/behavioral decay with respect to his or her standard on clinical examination or to the caregivers	Clinical findings usually not reproducible
Grade II	Overt	<ul style="list-style-type: none"> <li>• Lethargy or apathy</li> <li>• Disorientation for time</li> <li>• Obvious personality change</li> <li>• Inappropriate behavior</li> <li>• Dyspraxia</li> <li>• Asterixis</li> </ul>	Disoriented for time (at least three of the followings are wrong: day of the month, day of the week, month, season, or year) ± the other mentioned symptoms	Clinical findings variable, but reproducible to some extent
Grade III		<ul style="list-style-type: none"> <li>• Somnolence to semistupor</li> <li>• Responsive to stimuli</li> <li>• Confused</li> <li>• Gross disorientation</li> <li>• Bizarre behavior</li> </ul>	Disoriented also for space (at least three of the following wrongly reported: country, state [or region], city, or place) ± the other mentioned symptoms	Clinical findings reproducible to some extent
Grade IV		Coma	Does not respond even to painful stimuli	Comatose state usually reproducible